<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report a patient with a previously known <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> who had life threatening multiple arterial thromboses </plain></SENT>
<SENT sid="1" pm="."><plain>The patient experienced a <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> with intraventricular <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> under <z:chebi fb="0" ids="3181">bromocriptine</z:chebi> therapy in the puerperium, despite prophylactic low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> therapy </plain></SENT>
<SENT sid="2" pm="."><plain>In this patient, no microvascular involvement was identified, thus eliminating the diagnosis of catastrophic <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Arterial thromboses may be explained by peripheral emboli originating from the intraventricular <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>This case emphasizes the necessity of a careful evaluation of the risk-benefit balance of <z:chebi fb="0" ids="3181">bromocriptine</z:chebi> therapy in patients with arterial risk factors </plain></SENT>
<SENT sid="5" pm="."><plain>It also emphasizes the need for a correct diagnosis of catastrophic <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> allowing to limit the prescription of aggressive therapies </plain></SENT>
</text></document>